Clinical trial
CCI-779 in Treating Patients With Advanced Solid Tumors
NCT00003712 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00003712 |
|---|---|
| Title | CCI-779 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Texas Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | temsirolimus |
| Enrollment | 15 |
| Start date | Jan 1, 2001 |
| Primary completion | Jun 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Jul 15, 2003 |
| Last update posted | Aug 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: